# Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval

**Source:** Endpoints News
**URL:** https://e.endpointsnews.com/t/t-l-wpiudl-jykykhhuld-k/
**Date:** 2026-01-07

---

Martin Babler, Alumis CEO

January 6, 2026 11:22 AM EST R&D

Alu­mis' TYK2 drug suc­ceeds in key pso­ri­a­sis stud­ies, will seek FDA ap­proval

Lei Lei Wu

News Reporter

Alu­mis re­port­ed its ex­per­i­men­tal pill helped clear skin symp­toms from pso­ri­a­sis across two Phase 3 tri­als, trig­ger­ing a surge in the Bay Area biotech’s stock …

---

#news #endpoints-news
